TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04100083
Drug: Spironolactone 200 mg
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria.
Study: NCT02903121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
Study: NCT03363854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Study: NCT01430520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
Study: NCT03611153
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.
Study: NCT03837977
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm I
Study: NCT03755804
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously (IV)
Study: NCT03755804
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV)
Study: NCT03316898
Drug: AGN-242071
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
Study: NCT03316898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
Study: NCT03147612
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03147612
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecally or IV
Study: NCT00406250
Drug: intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg in 0.05 cc of bevacizumab
Study: NCT00406250
Drug: intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg of bevacizumab intravitreally injected in a steril field
Study: NCT01070511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
Study: NCT01254136
Drug: INCB007839 300mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
Study: NCT03283813
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
Study: NCT03283813
Drug: Myoinositol
Normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
Study: NCT03727802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and multiple doses (4 weeks)
Study: NCT03377543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81mg non-active pill that looks like aspirin
Study: NCT04429542
Drug: BCA101
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR/TGFβ fusion monoclonal antibody
Study: NCT00278213
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02260791
Drug: Humira®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
Study: NCT00078715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
Study: NCT01689935
Drug: 20 % Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical medication for ALA-PDT and i-PDT
Study: NCT00719693
Drug: ABT-143 ( rosuvastatin calcium and fenofibric acid )
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: one dose under low-fat meal condition
Study: NCT00719693
Drug: ABT-143 (rosuvastatin calcium and fenofibric acid )
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: one dose under fasting meal condition
Study: NCT01612494
Drug: Hypertonic Saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
Study: NCT02205229
Drug: Multi-ingredient, topical compounded medications
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03729128
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.
Study: NCT04460352
Drug: Oxaliplatin, calcium folinate, 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.
Study: NCT02715115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry flavored solution and Water for Injection
Study: NCT00561964
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group: 2 placebo capsules daily as a single morning intake
Study: NCT00630942
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 100 mg capsules twice a day before breakfast and before dinner.
Study: NCT01494727
Drug: Novartis Exforge 10/160mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT02143414
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02143414
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02143414
Drug: Methotrexate Sodium
Normalized name: Methotrexate Sodium
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02491684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution for once daily inhalation for 14 days
Study: NCT04432454
Drug: Lasofoxifene and abemaciclib (VERZENIO (R)).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasofoxifene 5 mg given once a day orally and abemaciclib 150 mg given twice a day orally.
Study: NCT00598585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills 3X/day for 6 weeks
Study: NCT00902122
Drug: p53 gene therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
Study: NCT03160118
Drug: Seasonal,quadrivalent,influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose to be administered on Day 0, the first visit
Study: NCT00846885
Drug: Imitrex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Tablet
Study: NCT02616523
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
Study: NCT02178553
Drug: Epidural
Normalized name: Epidural 17g 3.5"
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02185209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Place capsule to mimic antibiotics
Study: NCT00641771
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
Study: NCT03631602
Drug: antifungal prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: posaconazole oral suspension vs itraconazole oral solution
Study: NCT04524949
Drug: IMCY-0098 450 μg
Normalized name: urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small synthetic peptide for SC admin. Solvent: alum hydroxide
Study: NCT04524949
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solvent: alum hydroxide
Study: NCT02946580
Drug: MOVANTIK™ (naloxegol)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00135694
Drug: calcineurin inhibitor-based immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: May be cyclosporine, mycophenolate mofetil, or tacrolimus
Study: NCT00135694
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-month course of corticosteroids
Study: NCT02000674
Drug: Succinylcholine : 1mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03851835
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six doses of oral placebo (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
Study: NCT02735863
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg or 150mg once daily for 28 days
Study: NCT02735863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 matching placebo
Study: NCT03059069
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients maintain their medication with either Gliatamin or placebo for 6 months.
Study: NCT01359319
Drug: Sialic Acid Extended Release (SA-ER) Tables
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
Study: NCT03580707
Drug: BRV vs LEV in randomized double blinded, crossover fashion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
Study: NCT02114346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01038609
Drug: Hydrocodone/Acetaminophen Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01038609
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01927744
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
Study: NCT00267267
Drug: ezetimibe/simvastatin
Normalized name: EZETIMIBE/SIMVASTATIN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01871428
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching aleglitazar placebo orally daily
Study: NCT01314261
Drug: ABT-267
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg or 25 mg tablets
Study: NCT00173472
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01780311
Drug: antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00656981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
Study: NCT00328939
Drug: ARIXTRA infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00142155
Drug: monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04206553
Drug: Oral corticosteroids (OCS)
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone or prednisolone per standard of care to obtain control of disease activity.
Study: NCT00567398
Drug: Dianeal
Normalized name: Dianeal PD-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)
Study: NCT00567398
Drug: Physioneal
Normalized name: Physioneal 40 with 1.36% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physioneal 40 or Physioneal 35
Study: NCT01143818
Drug: AndroGel (testosterone gel) 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
Study: NCT01756209
Drug: Ibuprofen 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 10 mg/kg oral single dose
Study: NCT01756209
Drug: acetaminophen 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 15 mg/kg oral single dose
Study: NCT00689728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a single IV infusion over 30 minutes.
Study: NCT02892357
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
Study: NCT02892357
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
Study: NCT03575052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, tablets, once daily by mouth (provided as two placebo tablets)
Study: NCT04233112
Drug: Melatonin 5 mg
Normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsules containing 5mg melatonin will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
Study: NCT04233112
Drug: Placebo (plant fiber) for melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
Study: NCT04069689
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match EPX-100
Study: NCT03576456
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive placebo prior to angio
Study: NCT02715609
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00193856
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
Study: NCT00106496
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical
Study: NCT00106496
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical
Study: NCT00982800
Drug: Placebo Sugar Pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00715780
Drug: soluble human insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00715780
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT01607957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
Study: NCT02201108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet, Route of administration: oral
Study: NCT03535727
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO twice daily (BID); Days 1-7, 15-21
Study: NCT03535727
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO BID; Days 1- 14
Study: NCT00027846
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA\<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
Study: NCT04519164
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mineralocorticoid receptor antagonist and potassium-sparing diuretic
Study: NCT04519164
Drug: Chlorthalidone with potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: potassium-wasting diuretic with potassium chloride
Study: NCT01401179
Drug: cefazolin, erythromycin, clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
Study: NCT03308799
Drug: MC2-01 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
Study: NCT03308799
Drug: Cal/BDP combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%
Study: NCT03067467
Drug: Hyperpolarized 13C-Pyruvate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.
Study: NCT02008396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapy.
Study: NCT00211536
Drug: Medtronic MiniMed Implantable Pump Human Recombinant Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
Study: NCT03055377
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
Study: NCT04301349
Drug: vaginal dinoprostone
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion
Study: NCT04301349
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two tablets of placebo given 3 hours prior to IUD insertion
Study: NCT02049385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01243047
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib, Oxaliplatin, Capecitabine
Study: NCT00768040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo once daily
Study: NCT01908335
Drug: PEG-IFN-SA /RBV low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Study: NCT01908335
Drug: PEG-IFN-SA /RBV middle dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
Study: NCT01908335
Drug: PEG-IFN-SA /RBV high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3